Covered recipient · General Payments record
REBECCA DUNSMOOR SU
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2021–2024
$15,346.86
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,865.00 | 3 |
| Food and Beverage | $348.15 | 7 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $5,579.14 | 7 |
| Incyte Corporation | $510.00 | 1 |
| Astellas Pharma Global Development | $80.58 | 1 |
| GlaxoSmithKline, LLC. | $43.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Global Development | $80.58 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132966069 | CMS |
| GlaxoSmithKline, LLC. | $43.43 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116712413 | CMS |
| Incyte Corporation | $510.00 | 04/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141219090 | CMS |
| Novo Nordisk Inc | $29.80 | 01/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097126631 | CMS |
| Novo Nordisk Inc | $595.00 | 05/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097499437 | CMS |
| Novo Nordisk Inc | $4,760.00 | 06/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097498010 | CMS |
| Novo Nordisk Inc | $31.25 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097770785 | CMS |
| Novo Nordisk Inc | $117.82 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097514171 | CMS |
| Novo Nordisk Inc | $25.14 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097052116 | CMS |
| Novo Nordisk Inc | $20.13 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097406250 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.